Ford’s new vehicle sales slow in August, in line with expectations

Ford’s new vehicle sales slow in August, in line with expectations


2023 Ford F-150 Raptor R

Ford

DETROIT – Ford Motor on Friday said its U.S. sales last month increased double-digits from a year earlier but were off about 4% from the prior month, as the company and auto industry continue to manage significant supply chain issues.

The Detroit automaker reported August sales of 158,088 new vehicles in the U.S., a 27% increase from August 2021, when the company’s production and sales were significantly impacted by a shortage of semiconductor chips. Last month’s sales were down 3.6% compared to July, including an 8% decline in its F-Series pickup trucks.

Those sales were in line with analyst expectations, though. The company said its Ford brand was America’s best-selling brand for a second consecutive month.

Sales of Ford’s profitable F-Series pickups were up 1.7% for the month from August 2021 but off 10.7% for the first eight months of the year compared with the same period last year. The company has sold 6,842 models of its all-electric F-150 Lightning pickup as of Aug. 31, including 2,373 vehicles last month.

“F-Series was America’s best-selling truck, best-selling hybrid truck and best-selling electric truck with F-150 Lightning in August. Ford’s overall electric vehicle portfolio expanded four–fold in July, while conquesting from competitors at a rate over 60%,” Andrew Frick, Ford vice president of sales, distribution and trucks, said in a release.

Ford’s 2022 electric vehicle sales totaled more than 36,500 units through August. That included sales of about 5,900 vehicles in August, which was 23% lower than the prior month but up more than 300% from a year ago.

Year-to-date sales of all Ford’s vehicles, including its luxury Lincoln brand, totaled more than 1.2 million units through August, a 0.2% decrease from a year ago. At the end of last month, the automaker’s U.S. vehicle inventory, including dealer stock and in-transit vehicle, was about 259,000 units, up from 245,000 in July.

J.D. Power and LMC Automotive estimate total U.S. new vehicle sales last month topped 980,000 units, which would be 2.6% lower than August 2021 – the first month the auto industry’s vehicle inventories were significantly impacted by an ongoing shortage of semiconductor chips.

RBC Capital Markets said the seasonally adjusted annualized rate, or SAAR, for new vehicles was 13.4 million, slightly higher than its 13.2 million forecast and in line with July’s 13.5 million. The SAAR is a closely watched metric by analysts and investors.



Source

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored
Business

CDC says there are no U.S. hantavirus cases currently, 41 people being monitored

In this photo illustration Hantavirus samples are seen in Ankara, Turkiye on May 6, 2026. Arman Onal | Anadolu | Getty Images The U.S. Centers for Disease Control and Prevention said there are no hantavirus cases in the country as of Thursday, as it monitors 41 people for the virus. The agency said the risk […]

Read More
These three artworks could sell for 0 million each next week as May auctions begin
Business

These three artworks could sell for $100 million each next week as May auctions begin

A large-scale Jackson Pollock drip painting titled, “Number 7A, 1948.” Crystal Lau | CNBC A version of this article first appeared in CNBC’s Inside Wealth newsletter with Robert Frank, a weekly guide to the high-net-worth investor and consumer. Sign up to receive future editions, straight to your inbox. Nearly $2 billion worth of art will come up […]

Read More
Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data
Business

Biogen advances Alzheimer’s drug to late-stage trial despite disappointing data

A Biogen facility in Cambridge, Massachusetts. Brian Snyder | Reuters Biogen plans to advance an experimental drug for Alzheimer’s disease to late-stage testing despite disappointing mid-stage trial data, the company said Thursday. Biogen said its experimental drug that targets tau, a protein associated with the memory-robbing disease, failed to show better responses at higher doses. […]

Read More